

TABLE OF STATUTES AND REGULATIONS

Research current through June 2014.

This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2014 Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

	Drugs Monitored: Schedules II- V	Drugs Monitored: Non- controlled	Training/ Education	De-identified Data	Interstate Sharing: Other PMPs	Interstate Sharing: Authorized Users	Interstate Sharing: Both
Alabama	§ 20-2-213				§ 20-2-214		
Alaska	§ 17.30.200					12 AAC 52.855	
Arizona				§ 36-2604			§ 36-2604
Arkansas	§ 20-7-603 & -604			§ 20-7-607	§ 20-7-608; ADC 007.07.4-VIII		
California				H&S § 11165		Website	
Colorado	§ 12-42.5-402 & -403			§ 12-42.5-404		§ 12-42.5-404	
Connecticut	§ 21a-254			ADC 21a-254-6			§ 21a-274; §20- 578
Delaware	16 § 4798	16 § 4798		16 § 4798	16 § 4798		
District of Columbia	§ 48-853.01	§ 48-853.01		§ 48-853.05	§ 48-853.06		
Florida							
Georgia	§ 16-13-59			§ 16-13-60			
Hawaii	§ 329-102	§ 329-102			§ 329-104		
Idaho	§ 37-2726	§ 37-2726		§ 37-2730A		§ 37-2726	
Illinois	720 § 570/316	720 § 570/316		720 § 570/318	720 § 570/318; ADC 77 § 2080.211		
Indiana	§ 35-48-7-8.1			§ 35-48-7-11.1			§ 35-48-7-11.1; § 35-48-7-5.4
Iowa						§ 124.553	
Kansas		ADC 68-21-7		§ 65-1685	ADC 68-21-5 & -6		
Kentucky	§ 218A.202		§ 218A.202; § 218A.240	§ 218A.240			§ 218A.202; § 218A.245; § 218A.390

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Louisiana	§ 40:1006	§ 40:1006	§§ 40:1007	§ 40:1007			§ 40:1007; ADC
			& 40:1008				Tit. 46, Pt. LIII, §§
							2917 & 2921
Maine				22 § 7250	22 § 7250; 22 §§		
					7261 - 7274		
Maryland	Health-Gen.			Health-Gen.	Health-Gen. § 21-		
	§ 21-2A-02			§ 21-2A-06	2A-06; ADC		
					10.47.07.04		
Massachusetts	94C § 24A	94C § 24A	94C § 24A	94C § 24A	94C § 24A; 105		
					CMR 700.012		
Michigan	§ 333.7333a						§ 333.7333a
Minnesota						§ 152.126	
Mississippi	§ 73-21-127	§ 73-21-127		§ 73-21-127	§ 73-21-127		
Missouri							
Montana	§ 37-7-101		Admin.	ADC	§ 37-7-1506		
				24.174.1713			
Nebraska							
Nevada			§ 453.1545	§ 453.1545	§ 453.1545		
New					§ 318-B:35		
Hampshire							
New Jersey	§ 45:1-45	§ 45:1-47	Admin.	§ 45:1-46			§ 45:1-46
New Mexico	ADC 16.19.29		ADC	ADC 16.19.29			ADC 16.19.29
			16.19.29				
New York	PH § 3343-a						PH § 3371-a
North Carolina	§ 90-113.73			§ 90-113.74	§ 90-113.74		
North Dakota	ADC 61-12-	ADC 61-12-01-		§ 19-03.5-03			§ 19-03.5-06 & -
	01-01 & -02	01 & -02					08
Ohio	§ 4729.75	§ 4729.75	ADC 4723-9-	§ 4729.80			§ 4729.80
			02 & -13				
Oklahoma	63 § 2-309C			63 § 2-309D	63 § 2-309D (eff.		
					Nov. 1, 2014)		
Oregon				§ 431.966			§ 431.960 &
							§ 431.966

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Pennsylvania			Admin.				
Rhode Island				§ 21-28-3.32	NABP		
				ADC 31-2-1:3.0			
South Carolina			Website	§ 44-53-1650			§ 44-53-1650
South Dakota				§ 34-20E-7	§ 34-20E-14		
Tennessee	§ 53-10-304			§ 53-10-306			§§ 53-10-311, -
							302 & -303
Texas	H&S §			H&S § 481.076		H&S §	
	481.074					481.076	
Utah	§ 58-37-2		§ 58-37f-402	§ 58-37f-301;	§ 58-37f-301		
				ADC R156-37f;			
				ADC R384-203			
Vermont			18 § 4282;	18 § 4284			18 § 4284;
			ADC 12-5-				18 § 4288
			21:4				
Virginia		§ 54.1-2519		§ 54.1-2523	§ 54.1-2523		
Washington	§ 70.225.020	§ 70.225.020		§ 70.225.040			ADC 246-470-070
West Virginia	ADC § 15-11-		§ 60A-9-5	§ 60A-9-5			§ 60A-9-5 & ADC §
	4						15-8-7
Wisconsin	ADC Pharm	§ 450.19; ADC		ADC Pharm			§ 450.19; ADC
	18.03	Pharm 18.03		18.11			Pharm 18.11 &
							18.14
Wyoming		ADC AI PDSC		§ 35-7-1060		§ 35-7-1060	
		Ch. 8, § 7					

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

	Unsolicited Reports	Data Confidentiality: Not subject to public or open records laws	Data Confidentiality: Penalties for disclosing data	Data Confidentiality: Penalties for Wrongly using data	Data Confidentiality: Penalties for wrongly Obtaining data	Mandatory Utilization	Mandatory Enrollment
Alabama	2010 Survey	§ 20-2-215	§ 20-2-216		§ 20-2-216		§ 34-24-604; ADC 540-X-4- .03; ADC 540-X- 1205; ADC 540-X-1805; ADC 540-X-19- .03 &04
Alaska	2009 Survey	§ 17.30.200	§ 17.30.200		§ 17.30.200		
Arizona	§ 36-2604	§ 36-2604	§ 36-2610			§ 23-1062.02	§ 36-2606
Arkansas	§ 20-7-607	§ 20-7-606	§ 20-7-611; ADC 007.07.4-XI	§ 20-7-611; ADC 007.07.4-XI	§ 20-7-611; ADC 007.07.4-XI		
California	H&S § 11165.1		Civ. § 56.36	Civ. §56.36	Civ. § 56.36		H&S § 11165.1
Colorado	§ 12-42.5- 404		§ 12-42.5-406		§ 12-42.5-406	2 CCR 502- 1:21.320.3 & 7 CCR 1101- 3:18	§ 12-42.5-403
Connecticut	ADC 21a- 254-5						§ 21a-317; ADC §§ 21a-408-2 & -38
Delaware	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798
District of Columbia	§ 48-853.07	§ 48-853.05	§ 48-853.09	§ 48-853.09			
Florida	§ 893.055	§ 893.0551					
Georgia		§ 16-13-60	§ 16-13-64	§ 16-13-64	§ 16-13-64		
Hawaii	§ 329-103	§ 329-104	§ 329-104	§ 329-104			

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Idaho	§ 37-2730A		§ 37-2726		§ 37-2726		§§ 37-2716 & 37-2726
Illinois	720 §						37-2720
11111013	570/314.5						
Indiana	§ 35-48-7-					§ 35-48-7-	
	11.1					12.1	
Iowa		§ 124.553	§ 124.558	§ 124.558	§ 124.558		
Kansas	§ 65-1685	§ 65-1685	§ 65-1693	§ 65-1693	§ 65-1693		
Kentucky	§ 218A.240	§ 218A.202	§ 218A.202		§ 218A.202	§ 218A.172; 201 KAR 8:540, 9:016, 9:260, 20:057 & 25:090	§ 218A.202; 201 KAR 5:130, 9:230, 25:011 & 25:021
Louisiana	§ 40:1007	§ 40:1007	§ 40:1009	§ 40:1009		§ 40:978 & 48 ADC Pt. I, § 7831	
Maine	22 § 7250	22 § 7250	22 § 7251	22 § 7251			Sec. 2 (LD 1840)
Maryland	Health- General § 21-2A-06 (eff. Oct. 1, 2014)	Health-General § 21-2A-06; CMR 10.47.07.06	Health-General § 21-2A-09	Health-General § 21-2A-09	Health-General § 21-2A-09		
Massachusetts	94C § 24	94C § 24A	105 ADC 700.012	105 ADC 700.012	105 ADC 700.012	Multiple statutes and regulations ¹	94C § 7A
Michigan	Admin. ²	§ 333.7333a					
Minnesota	§ 152.126	§ 152.126	§ 152.126			§254A.192	
Mississippi	§ 73-21-127	§ 73-21-127				ADC 24-2:59.2	ADC 30-17- 2640:1.15

٠

¹ 94C § 24A; 105 CMR 725.010; 234 CMR 5.06; 243 CMR 2.07; 247 CMR 9.04; 249 CMR 4.02; & 263 CMR 5.07

² Michigan sends alerts to physicians when patients surpass set thresholds, but does not send the actual report.

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Missouri							
Montana	§ 37-7-1504		§ 37-7-1513	§ 37-7-1513			
Nebraska							
Nevada	§ 453.1545					§ 639.23507	
New Hampshire	§ 318-B:35	§ 318-B:34	§ 318-B:36	§ 318-B:36	§ 318-B:36		§ 318-B:33
New Jersey	§ 45:1-46	§ 45:1-46	§ 45:1-49	§ 45:1-49			
New Mexico	ADC 16.19.29	ADC 16.19.29	Admin.		Admin.	Multiple regulations ³	ADC 16.5.57, 16.10.14, 16.16.15, 16.17.5, 16.19.20 & 16.21.9
New York	PH § 3343-a					PH § 3343-a; 10 ADC 80.63	
North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.75		§ 90-113.75	Admin.	
North Dakota	§ 19-03.5-06		§ 19-03.5-10	§ 19-03.5-10		ADC 75-09.1- 10-10	
Ohio	§ 4729.81	§ 4729.80	§ 4729.86 & § 4729.861 (eff. Jan. 1, 2015)		§ 4729.86 & § 4729.861 (eff. Jan. 1, 2015)	Multiple statutes and regulations ⁴	Multiple statutes ⁵
Oklahoma	63 § 2-309G	63 § 2-309D	63 § 2-309D			63 § 2-302	
Oregon		§ 431.966	§ 431.970	§ 431.970			
Pennsylvania	18 § 9102						
Rhode Island	ADC 31-2- 1:3.0				§ 21-28-3.32	ADC § 46-1- 13:45.0	
South Carolina	§ 44-53-1650	§ 44-53-1650	§ 44-53-1680	§ 44-53-1680			
South Dakota	§ 34-20E-12		§ 34-20E-19				

³ ADC 16.5.57; 16.10.14; 16.12.9; 16.16.15; 16.17.5; 16.19.4; & 16.21.9

⁴ OH ADC 4729-5-20; § 4731.055; ADC 4731-11-11; § 4715.302; ADC 4715-6-01; § 4723.487; ADC 4723-9-12; § 4725.092; § 4729.162; § 4730.53; ADC 4723-6-21.4; ADC 4725-16-04; ADC 4730-2-10

⁵ §§ 4715.14; 4723.486; 4725.16; 4729.12; 4730.48; Sec. 747.30 (HB 483). The statutes go into effect on January 1, 2015.

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Tennessee	§ 53-10-305	§ 53-10-306	§ 53-10-306	§ 53-10-306	§ 53-10-306	Multiple statutes and regulations ⁶	§ 53-10-305
Texas	2010 Survey		H&S § 481.127		H&S § 481.127		
Utah	§ 58-37f-702		§ 58-37f-601	§ 58-37f-601	§ 58-37f-601		§ 58-37f-401
Vermont	18 §4284	18 § 4284	18 § 4284		18 § 4284	18 § 4289; 18	18 § 4289; ADC
						§ 4290; ADCA	12-5-102:2
						12-5-102:2; &	
						Sec. 13 (SB	
						295)	
Virginia	§ 54.1-2523	§ 54.1-2523	§ 54.1-2525	§ 54.1-2525		§ 54.1-2522.1	§ 54.1-2522.1
						(eff. July 1,	(eff. July 1,
						2015)	2015)
Washington	Admin.		§ 70.225.060	§ 70.225.060		ADC 296-20-	
						03035, 296-	
						20-03056, &	
						388-877B-	
						0440	
West Virginia	§ 60A-9-5		§ 60A-9-7	§ 60A-9-7	§ 60A-9-7	Multiple	ADC 5-10-3, 11-
						statutes and	10-3, 19-14-3 &
						regulations ⁷	24-7-3
Wisconsin	2010 Survey	ADC Pharm	ADC Pharm				
		18.13	18.13				
Wyoming	§ 35-7-1060						

⁶ § 53-10-310; ADC 1140-11-.06; ADC 1200-34-01-.07; ADC 0940-05-42-.07; ADC 0940-05-42-.15; ADC 0940-05-42-.17

⁷ WV § 16-5H-4, § 60A-9-5a, ADC §§ 5-10-1, 5-10-3, 11-10-1, 11-10-3, 19-14-1, 19-14-3, 24-7-1, 24-7-3, 69-7-27, and 69-7-42.

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Types of Authorized Recipients:	Coroners/ MEs	Licensing/ Regulatory Boards	Medicaid/Medicare/ State Health Ins. Programs	Patient or Parent of Minor	Prescribers & Dispensers	Substance Abuse/ Mental Health Profs.	Work Comp Specialists
Alabama		§ 20-2-214	§ 20-2-214		§ 20-2-214		
Alaska		§ 17.30.200		§ 17.30.200; 12 AAC 52.875	§ 17.30.200; 12 AAC 58.855		
Arizona		§ 36-2604	§ 36-2604	§ 36-2604	§ 36-2604		§ 36-2604; § 23-1026
Arkansas	§ 20-7-607; ADC 007.07.4- VII	§ 20-7-606 & -607; ADC 007.07.4-VI & - VII		§ 20-7-607; ADC 007.07.4-VII	§ 20-7-607; ADC 007.07.4-VII		
California		H&S § 11165			H&S § 11165.1		
Colorado	§ 12-42.5-404; 3 CCR 719- 1:23.00.00	§ 12-42.5-404; 3 CCR 719- 1:23.00.00		§ 12-42.5- 404; 3 CCR 719- 1:23.00.00	§ 12-42.5-404; 3 CCR 719- 1:23.00.00	§ 12-42.5- 404	
Connecticut		§ 20-578; ADC 21a-254-6			§ 21a-254; ADC 21a-254-6		
Delaware	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	
District of Columbia	§ 48-853.05	§ 48-853.05	§ 48-853.05	§ 48-853.05	§ 48-853.03		
Florida		§ 893.0551; ADC 64K-1.003	§ 893.0551; ADC 64K-1.003	§ 893.0551; ADC 64K- 1.003	§ 893.0551; ADC 64K-1.003		
Georgia		§ 16-13-60		§ 16-13-60	§ 16-30-60		
Hawaii					§ 329-104		
Idaho		§ 37-2726	§ 37-2726	§ 37-2726	§ 37-2726; ADC 27-01-01-204		
Illinois		720 § 570/318		720 § 570/318	720 § 570/318		

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Indiana		§ 35-48-7-11.1	§ 35-48-7-11.1		§ 35-48-7-11.1	§ 35-48-7-	
						11.1	
lowa		ADC 657-37.4		§ 124.553;	§ 124.553; ADC		
				ADC 657-	657-37.4		
				37.4			
Kansas	§ 65-1685	§ 65-1685; ADC	§ 65-1685; ADC 68-	§ 65-1685;	§ 65-1685; ADC		
		68-21-5	21-5	ADC 68-21-5	68-21-5		
Kentucky	§ 218A.202;	§ 218A.202	§ 218A.202	§ 218A.202	§ 218A.202		
	902 KAR						
	55:110						
Louisiana		§ 40:1007; ADC	§ 40:1007; ADC Tit.	§ 40:1007;	§ 40:1007; ADC		
		Tit. 46, Pt. LIII, §§	46, Pt. LIII, §§ 2917 &	ADC Tit. 46,	Tit. 46, Pt. LIII,		
		2917 & 2921	2921	Pt. LIII, §	§§ 2917 & 2921		
				2921			
Maine	22 § 7250; ADC	22 § 7250; ADC	22 § 7250; ADC 14-	22 § 7250;	22 § 7250; ADC		
	14-118, Ch. 11,	14-118, Ch. 11,	118, Ch. 11,	ADC 14-118,	14-118, Ch. 11,		
	§ 7	§ 7	§ 7	Ch. 11,	§ 7		
				§ 7			
Maryland	Health-Gen.	Health-Gen.	Health-Gen. § 21-2A-	Health-Gen.	Health-Gen.	Health-Gen.	
	§ 21-2A-06;	§ 21-2A-06; ADC	06; ADC 10.47.07.04	§ 21-2A-06;	§ 21-2A-06;	§ 21-2A-06;	
	ADC	10.47.07.04		ADC	ADC	ADC	
	10.47.07.04			10.47.07.04	10.47.07.04	10.47.07.04	
Massachusetts		94C § 24A; 105	94C § 24A; 105 CMR	94C § 24A;	94C § 24A; 105		
		CMR 700.012	700.012	66A § 2; 105	CMR 700.012		
				CMR			
				700.012			
Michigan		§ 333.7333a	§ 333.7333a		§ 333.7333a		
Minnesota	Admin.	§ 152.126	§ 152.126	§ 152.126	§ 152.126	§ 152.126	
Mississippi	Admin.	§ 73-21-127	§ 73-21-127	§ 73-21-127	§ 73-21-127		
Missouri							
Montana	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506		§ 39-71-
							1110
Nebraska							

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Nevada		§ 453.1545	§ 453.1545	§ 453.1545	§ 453.1545		
New		§ 318-B:35		§ 318-B:35	§ 318-B:35		
Hampshire							
New Jersey		§ 45:1-46	§ 45:1-46		§ 45:1-46		
New Mexico	Admin.	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29		
New York	PH § 3371	PH § 3371	PH § 3371	PH § 3343-a & 3371	PH § 3343-a & 3371		
North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.74	§ 90-113.74	§ 90-113.74		
North Dakota	Admin.	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5- 03
Ohio		§ 4729.80; ADC 4729-37-08	§ 4729.80; § 5167.14; ADC 4729-37-08	§ 4729.80; ADC 4729- 37-08	§ 4729.80; ADC 4729-37-08		§ 4729.80; ADC 4123- 6-21.4
Oklahoma		63 § 2-309D			63 § 2-309D	63 § 2-309D	
Oregon	§ 431.966	§ 431.966; ADC 410-121-4020		§ 431.966; ADC 410- 121-4020	§ 431.966; ADC 410-121-4020		
Pennsylvania							
Rhode Island		§ 21-28-3.32 ADC 31-2-1:3.0		§ 21-28-3.32	§ 21-28-3.32		
South Carolina		§ 44-53-1650	§ 44-53-1650	§ 44-53- 1650	§ 44-53-1650		
South Dakota		§ 34-20E-7; ADC 20:51:32:07	§ 34-20E-7	§ 34-20E-7; ADC 20:51:32:06	§ 34-20E-7; ADC 20:51:32:04 & :05		
Tennessee	§ 53-10-306	§ 53-10-308; § 53-10-306; ADC 1140-1102	§ 53-10-306	ADC 1140- 1102	§ 53-10-306; ADC 1140-11- .02	§ 53-10-306	
Texas		H&S § 481.076			H&S § 481.076		
Utah		§ 58-37f-301	§ 58-37f-301	§ 58-37f- 301; R156- 37f	§ 58-37f-301	§ 58-37f-301	§ 58-37f- 301

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Vermont	18 § 4284	18 § 4284; ADC	18 § 4284	18 § 4284;	18 § 4284; ADC	
		12-5-21:3		ADC 12-5-	12-5-21:3	
				21:3		
Virginia	§ 54.1-2523;	§ 54.1-2523; 18	§ 54.1-2523; 18 VAC	§ 54.1-2523;	§ 54.1-2523; 18	
	18 VAC 76-20-	VAC 76-20-60	76-20-60	18 VAC 76-	VAC 76-20-60	
	60			20-60		
Washington	ADC 246-470-	§ 70.225.040	§ 70.225.040	§ 70.225.040	§ 70.225.040;	§70.225.040
	060			ADC 246-	ADC 246-470-	
				470-040	050	
West Virginia	§ 60A-9-5	§ 60A-9-5; ADC	§ 60A-9-5		§ 60A-9-5; ADC	
		§ 15-8-7			§ 15-8-7	
Wisconsin	ADC Pharm	ADC Pharm 18.11		ADC Pharm	ADC Pharm	
	18.11			18.11	18.09	
Wyoming		ADC AI PDSC Ch.		§ 35-7-1060;	§ 35-7-1060;	
		8, § 3		ADC AI PDSC	ADC AI PDSC	
				Ch. 8, § 3	Ch. 8, § 3	

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Types of Authorized Recipients:	Delegates	Law Enforcement	Judicial Officials	Physicians' Assistants	Health Care Agent	Resident Physician	State Toxicologist
Alabama	§ 20-2-214	§ 20-2-214; ADC 420-7-213		§ 20-2-214			
Alaska		§ 17.30.200			12 AAC 52.875		
Arizona	§ 36-2604	§ 36-2604	§ 36-2604				
Arkansas		§ 20-7-606 & -607; ADC 007.07.4-VI & -VII	§ 20-7-607; ADC 007.07.4-VII				
California	Bus. & Prof. § 209	H&S § 11165	H&S § 11165				
Colorado	§§ 12-42.5-403 & 12-42.5-404	§ 12-42.5-404; 3 CCR 719- 1:23.00.00	§ 12-42.5-404; 3 CCR 719- 1:23.00.00		3 CCR 719- 1:23.00.00	§ 12-42.5- 404	
Connecticut		ADC 21a-254-6					
Delaware	16 § 4798	16 § 4798	16 § 4798				
District of Columbia	§ 48-853.04	§ 48-853.05	§ 48-853.05				
Florida		§ 893.055 & .0551; ADC 64K-1.003	§ 893.055 & .0551; ADC 64K-1.003		§ 893.0551; ADC 64K-1.003		
Georgia		§ 16-13-60	§ 16-13-60				
Hawaii		§ 329-104; ADC § 23-200-22	§ 329-104	§ 329-104			
Idaho	Admin.	§ 37-2726	§ 37-2726				
Illinois		720 § 570/318	720 § 570/318				
Indiana	§ 35-48-7-11.1	§ 35-48-7-11.1	§ 35-48-7-11.1				§ 35-48-7- 11.1
Iowa	§ 124.553; ADC 657-37.2 & -37.4	ADC 657-37.4	§ 124.553; ADC 657-37.4		ADC 657-37.4		
Kansas	ADC 68-21-5	§ 65-1685; ADC 68-21-5	§ 65-1685; ADC 68-21-5		ADC 68-21-5		

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Kentucky	§ 218A.202	§ 218A.202; §	§ 218A.202		§ 218A.202	
		218A.240; 902				
		ADC 55:110				
Louisiana	§ 40:1007	§ 40:1007; ADC Tit.	§ 40:1007; ADC			
		46, Pt. LIII, § 2921	Tit. 46, Pt. LIII, §			
			2921			
Maine	ADC 14-118, Ch.	Website			ADC 14-118	
	11, § 7				Ch. 11, § 7	
Maryland	Health-Gen.	Health-Gen. § 21-			ADC	
	§21-2A-06; ADC	2A-06; ADC			10.47.07.04	
	10.47.07.02 &	10.47.07.04				
	.04					
Massachusetts	94C § 24A	94C § 24A; 105	94C § 24A; 105		66A § 2	
		CMR 700.012	CMR 700.012			
Michigan		§ 333.7333a	§ 333.7333a			
Minnesota	§ 152.126; §	§ 152.126			§ 152.126	
	245A.192					
Mississippi		§ 73-21-127 & §	§ 41-29-187 &			
		41-29-187	73-21-127			
Missouri						
Montana	ADC	§ 35-7-1506				
	24.174.1701					
Nebraska						
Nevada		§ 453.1545 & §	§ 453.1545 & §			
		453.151	453.151			
New Hampshire		§ 318-B:35				
New Jersey		§ 45:1-46	§ 45:1-46			
New Mexico	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29	ADC		
				16.19.29		
New York	PH § 3343-a; 10	PH § 3371; 10 ADC	PH § 3371; 10		PH § 3343-a &	
	ADC 80.63	§ 80.107	ADC § 80.107		3371	
North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.74			

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

North Dakota	Admin.	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03		§ 19-03.5-	
						03	
Ohio	§ 4729.80	§ 4729.80; ADC	§ 4729.80				
		4729-37-08					
Oklahoma		63 § 2-309D	63 § 2-309D				
Oregon	§ 431.966	§ 431.966; ADC					
		410-121-4020					
Pennsylvania		18 § 9102 & 35 §	18 § 9102 & 35 §				
		780-137	780-137				
Rhode Island	§ 21-28-3.32	§ 21-28-3.32					
		ADC 31-2-1:3.0					
South Carolina	§§ 44-53-1630 &	§ 44-53-1650	§ 44-53-1650				
	44-53-1650						
South Dakota	Admin.	§ 34-20E-7; ADC	§ 34-20E-7; ADC		ADC		
		20:51:32:08	20:51:32:08 &		20:51:32:06		
			:09				
Tennessee	§ 53-10-306 & -	§ 53-10-306 & -	§ 53-10-306;				
	302	309; ADC 1140-11-	ADC 1140-1102				
		.02					
Texas	H&S § 481.076	H&S § 481.076; 37	H&S § 481.076;	H&S §			
		ADC § 13.82	37 ADC § 13.82	481.076			
Utah	§ 58-37f-301;	§ 58-37f-301;	§ 58-37f-301;		ADC R156-37f		
	R156-37f	R156-37f	R156-37f				
Vermont	18 §§ 4282 &	18 §§ 4282 &					
	4284	4284; ADC 12-5-					
		21:3 & :4					
Virginia	§ 54.1-2523.2	§ 54.1-2523; 18	§ 54.1-2523; 18				
		VAC 76-20-50	VAC 76-20-50				
Washington	ADC 246-470-	§ 70.225.040	§ 70.225.040		ADC 246-470-		
-	050				040		
West Virginia	§ 60A-9-5; ADC §	§ 60A-9-5; ADC §	§ 60A-9-5; ADC §				
-	15-8-7	15-8-7	15-8-7				

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Wisconsin	ADC Pharm § 146.82; ADC		§ 146.82	ADC Pharm	
	18.09	Pharm 18.11		18.11	
Wyoming		§ 35-7-1060; ADC		ADC AI PDSC	
		AI PDSC Ch. 8, § 3		Ch. 8, § 3	

© 2014 Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Types of Authorized Recipients:	Probation/ Parole Officer	Health Care Payment/ Benefit Provider/Insurer	Peer Review Committee	Attorney on Behalf of Patient	Quality Improvement Committee of Hospital	Department of Health
Alabama						
Alaska						
Arizona						
Arkansas						
California						
Colorado						
Connecticut						
Delaware						
Florida						
Georgia				§ 16-13-60		
Hawaii						
Idaho						
Illinois						
Indiana						
Iowa						
Kansas			§ 65-1685			
Kentucky	§218A.202					
Louisiana						
Maine						
Maryland						
Massachusetts						
Michigan		§ 333.7333a				
Minnesota						
Mississippi						
Missouri						
Montana						
Nebraska						
Nevada				§ 453.1545		
New Hampshire						

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

New Jersey					
New Mexico					ADC 16.19.29
New York					PH § 3371
North Carolina					
North Dakota	§ 19-03.5- 03		§ 19-03.5- 03		
Ohio					
Oklahoma					63 § 2-309D
Oregon					
Pennsylvania					
Rhode Island					
South Carolina					
South Dakota		§ 34-20E-7	§ 34-20E-7		
Tennessee				§ 53-10-306	
Texas					
Utah					§ 58-37f-301
Vermont					
Virginia			§ 54.1-2523		
Washington					
West Virginia					
Wisconsin					
Wyoming					

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

	Types of Authorized Recipients: Commissioner of Public Safety	Types of Authorized Recipients: Department of Corrections	Types of Authorized Recipients: Third Party with Signed Consent Form	Evaluation of PMP: Report to Legislature	Evaluation of PMP: Advisory Committee, Task Force, etc.	No Requirement to Access	Data Collection Interval
Alabama					§ 20-2-212	§ 20-2-214	Weekly
Alaska				§ 17.30.200		§ 17.30.200; 12 AAC 52.855	Monthly
Arizona					§ 36-2603		Daily
Arkansas					§ 20-7-605; ADC 007.07.4- V		Weekly
California							Weekly
Colorado				§ 12-42.5- 408.5	§ 12-42.5- 408.5		Twice monthly
Connecticut					§ 21a-254a		Weekly ⁸
Delaware				16 § 4798			Daily
District of Columbia					§ 48-853.02		Daily
Florida							7 days
Georgia					§ 16-13-61	§ 16-13-63	Weekly
Hawaii							7 days
Idaho			§ 37-2726				Weekly
Illinois					720 § 570/320	720 § 570/314.5 & 570/318	7 days
Indiana				§ 35-48-7-16		§ 35-48-7-11.1	7 days ⁹

[.]

⁸ Connecticut requires marijuana dispensaries to report daily.

⁹ Indiana is requiring that reporting be within 3 days by July 1, 2015 and within 24 hours by January 1, 2016.

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

lowa	§ 124.554 &	§ 124.555	§ 124.553	Weekly
	.555			
Kansas	§ 65-1691	§ 65-1689 <i>,</i> -	§ 65-1688	24 hours
		1690, -1691		
Kentucky		Exec. order		Daily
Louisiana	§ 40:1010	§ 40:1005; ADC		7 days (until Aug.
		Tit. 46, Pt. LIII §		1, 2014); daily
		2909		(eff. Aug. 1,
				2014)
Maine	Resolution	PMP Admin.		Weekly
Maryland	Health-Gen. §	Health-Gen.	Health-Gen.	3 days
	21-2A-05; Sec.	§ 21-2A-05 & -	§ 21-2A-04;	
	2 & 3 (HB 255)	07	ADC	
			10.47.07.08	
Massachusetts	94C § 24A	105 ADC		7 days
		700.012		
Michigan	§ 333.7112 &	§ 333.7112 &		Daily
	.7113	.7113		
Minnesota	§ 152.126 &	§ 152.126	§ 152.126	Daily
	Sec. 4 (HF			
	2402)			
Mississippi				7 days
Missouri				N/A
Montana	§ 37-7-1514	§ 35-7-1510		Weekly
Nebraska				N/A
Nevada		§ 453.1545		Weekly
New		§ 318-B:38		7 days
Hampshire				
New Jersey			§ 45:1-46	Twice monthly
New Mexico				7 days
New York	PH § 3309-a	PH § 3309-a		Real time
				(interpreted to

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

							mean within 24
							hours)
North Carolina					PMP Admin.		3 days
North Dakota					§ 19-03.5-07	§ 19-03.5-05	Daily
Ohio				§ 4729.85			Daily for
							pharmacies;
							monthly for
							wholesalers
Oklahoma						63 § 2-309D	Real time
						(eff. until Nov.	
						1, 2014)	
Oregon				§ 431.962 ¹⁰	§ 431.976 &	§ 431.966	7 days
					.978		
Pennsylvania							Monthly
Rhode Island							Monthly
South Carolina						§ 44-53-1680	Daily
South Dakota					§ 34-20E-15, -	§ 34-20E-11	Weekly
					16, -17		
Tennessee			ADC 1140-11-	§ 53-10-309	§ 53-10-303		7 days (until Jan.
			.02				1, 2016); Daily
							(eff. Jan. 1, 2016)
Texas				H&S §§	H&S §§		7 days
				481.351 &	481.351354		
				481.354			
Utah			R156-37f				Weekly; daily for
							pilot program
Vermont	18 § 4284			Uncodified			Weekly
Virginia					§ 54.1-2520		7 days
Washington		§ 70.225.040					Weekly
West Virginia				§ 60A-9-5	§ 60A-9-5		24 hours

¹⁰ Oregon does not require a report to the state legislature. It does require that the Oregon Health Authority, the body responsible for the operation of the PMP, make an annual report to the Prescription Monitoring Program Advisory Commission.

^{© 2014} Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Wisconsin	ADC Pharm		§ 450.19	7 days
	18.11			
Wyoming			ADC AI PDSC	7 days
			Ch. 8, § 3	

© 2014 Research is current as of June 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501